Elanco Animal Health Incorporated (NYSE:ELAN) Receives $19.14 Consensus Target Price from Brokerages

Elanco Animal Health Incorporated (NYSE:ELAN) has received a consensus rating of “Moderate Buy” from the eleven ratings firms that are covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $19.1429.

ELAN has been the subject of several research reports. UBS Group increased their price objective on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a “buy” rating in a report on Friday, August 8th. Stifel Nicolaus increased their price objective on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Leerink Partnrs raised shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 17th. William Blair raised shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating in a report on Thursday, June 26th. Finally, Zacks Research raised shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a report on Friday, October 3rd.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ELAN. Allworth Financial LP lifted its holdings in shares of Elanco Animal Health by 791.7% in the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock valued at $25,000 after acquiring an additional 2,090 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Elanco Animal Health by 79.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock valued at $43,000 after acquiring an additional 951 shares during the last quarter. First Horizon Advisors Inc. lifted its holdings in shares of Elanco Animal Health by 184.3% in the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock valued at $53,000 after acquiring an additional 2,414 shares during the last quarter. Wealthquest Corp bought a new position in shares of Elanco Animal Health in the 1st quarter valued at about $56,000. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in shares of Elanco Animal Health by 261.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company’s stock valued at $58,000 after acquiring an additional 2,922 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Down 0.0%

ELAN opened at $20.50 on Friday. The firm has a 50-day simple moving average of $18.81 and a two-hundred day simple moving average of $14.67. Elanco Animal Health has a 52 week low of $8.02 and a 52 week high of $21.76. The company has a market capitalization of $10.18 billion, a PE ratio of 23.84, a price-to-earnings-growth ratio of 3.76 and a beta of 1.65. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter in the prior year, the firm earned $0.30 EPS. The business’s revenue was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.